Salvage Therapy for Prostate Cancer - Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy

Publication Date: February 13, 2024
Last Updated: February 29, 2024

Summary of Recommendations

Clinicians should offer androgen deprivation therapy (ADT) in addition to salvage RT for patients with BCR following RP and any high-risk features (e.g., higher post-prostatectomy PSA such as PSA ≥0.7ng/mL, Gleason Grade Group 4 to 5, PSADT ≤6months, persistently detectable post-operative PSA, seminal vesicle involvement). (Moderate, B)
322859
For patients with BCR following RP without any high-risk features, clinicians may offer radiation alone. (Conditional, C)
322859
Clinicians should discuss treatment side effects and the impact of medical comorbidities when patients are being considered for ADT (as well as duration) with salvage RT, utilizing an SDM approach. (Clinical Principle, )
322859
For patients with pN1 disease being treated with post-operative RT, clinicians should include ADT rather than treating with RT alone. (Clinical Principle, )
322859
When providing ADT to patients undergoing salvage RT, clinicians should provide a minimum of four to six months of hormonal therapy. (Clinical Principle, )
322859
For patients with high-risk features, clinicians may extend ADT to 18 to 24 months. (Expert Opinion, )
322859
In patients with BCR following RP undergoing salvage RT with ADT, clinicians may use expanded radiation fields that include the regional lymph nodes. (Conditional, B)
322859
Clinicians should discuss with patients that including treatment of regional lymph nodes with salvage RT may increase the risk of side effects, particularly in the short term, compared to prostate bed RT alone. (Moderate, A)
322859
Clinicians should not recommend the addition of docetaxel in patients undergoing salvage RT and ADT. (Strong, B)
322859
For pN0 patients, clinicians should recommend the use of intensified androgen receptor (AR) suppression with salvage RT only within a clinical trial setting. (Clinical Principle, )
322859

Recommendation Grading

Disclaimer

The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.

Overview

Title

Salvage Therapy for Prostate Cancer - Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy

Authoring Organizations

American Society for Radiation Oncology

American Urological Association

Society of Urologic Oncology

Publication Month/Year

February 13, 2024

Last Updated Month/Year

April 1, 2024

Supplemental Implementation Tools

Document Type

Guideline

Country of Publication

US

Document Objectives

The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a 3-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis.

Inclusion Criteria

Male, Female, Adult, Older adult

Health Care Settings

Ambulatory, Outpatient, Radiology services

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Management

Keywords

prostate cancer, Biochemical Recurrence, BCR, non-metastatic prostate cancer

Source Citation

Morgan, Todd M.*; Boorjian, Stephen A.; Buyyounouski, Mark K.; Chapin, Brian F.; Chen, David Y. T.; Cheng, Heather H.; Chou, Roger; Jacene, Heather A.; Kamran, Sophia C.; Kim, Sennett K.; Kirkby, Erin; Luckenbaugh, Amy N.; Nathanson, Ben J.; Nyame, Yaw A.; Posadas, Edwin M.; Tran, Phuoc T.; Chen, Ronald C. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy, Journal of Urology:  - Volume 0 - Issue 0 doi: 10.1097/JU.0000000000003891

Supplemental Methodology Resources

Data Supplement

Methodology

Number of Source Documents
43
Literature Search Start Date
June 30, 2022
Literature Search End Date
July 25, 2023